Praxis Behandlungen Service Kontakt

Publikationsverzeichnis von Prof. Dr. med. Dierk Thomas

2020
1. Baumann S, Grau A, Senges J, Schneider S, Alonso A, Katus HA, Thomas D, Waldecker B, Haass M, Zahn R, Zeymer U, Akin I, Kruska M, Fischer C, Borggrefe M (2020) ARENA-Project atrial fibrillation in the Rhein-Neckar region. Herz 45: 689-695
2. Darche FF, Rivinius R, Rahm AK, Köllensperger E, Leimer U, Germann G, Reiss M, Koenen M, Katus HA, Thomas D, Schweizer PA (2020) In vivo cardiac pacemaker function of differentiated human mesenchymal stem cells from adipose tissue transplanted into porcine hearts. World J Stem Cells 12:1133-1151
3. Kany S, Brachmann J, Lewalter T, Kuck KH, Andresen D, Willems S, Hoffmann E, Eckardt L, Thomas D, Hochadel M, Senges J, Metzner A, Rillig A (2020) Safety and patient-reported outcomes in index ablation versus repeat ablation in atrial fibrillation: insights from the German Ablation Registry. Clin Res Cardiol doi: 10.1007/s00392-020-01763-1
4. Rahm AK, Lugenbiel P, Ochs M, Meder B, Thomas D, Katus HA, Scholz E (2020) Pulmonary vein isolation treats symptomatic AF in a patient with Lamin A/C mutation: case report and review of the literature. Clin Res Cardiol 109: 1070-1075
5. Rahm AK*, Müller ME*, Gramlich D, Lugenbiel P, Uludag E, Rivinius R, Ullrich ND, Schmack B, Ruhparwar A, Heimberger T, Weis T, Karck M, Katus HA, Thomas D (2020) Inhibition of cardiac Kv4.3 (Ito) channel isoforms by class I antiarrhythmic drugs lidocaine and mexiletine. Eur J Pharmacol 880: 173159
6. Rahm AK, Wieder T, Gramlich D, Müller ME, Wunsch MN, El Tahry FA, Heimberger T, Weis T, Most P, Katus HA, Thomas D, Lugenbiel P (2020) HDAC2-dependent remodeling of KCa2.2 (KCNN2) and KCa2.3 (KCNN3) K+ channels in atrial fibrillation with concomitant heart failure. Life Sci 266:118892
7. Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Darche FF, Thomas D, Bruckner T, Doesch AO, Katus HA, Ehlermann P (2020) Elevated pre-transplant pulmonary vascular resistance is associated with early post-transplant atrial fibrillation and mortality. ESC Heart Fail 7: 176-187
8. Schmidt C, Benda S, Kraft P, Wiedmann F, Pleger S, Büscher A, Thomas D, Wachter R, Schmid C, Eils R, Katus HA, Kallenberger SM (2020) Prospective multicentric validation of a novel prediction model for paroxysmal atrial fibrillation. Clin Res Cardiol doi: 10.1007/s00392-020-01773-z
9. Senn K, Zitron E, Katus HA, Thomas D, Ullrich C, Rahm AK (2020) Die Lebensqualität von Patienten mit implantierbarem Kardioverter-Defibrillator aus salutogenetischer Sicht: Eine qualitative Studie der kardiologischen Versorgungsforschung [Quality of life in patients with implantable cardioverter-defibrillator from a salutogenic perspective: A qualitative study in cardiologic health service research]. Herzschrittmacherther Elektrophysiol. 31: 301-306
10. Wagner L, Darche FF, Thomas D, Lugenbiel P, Xynogalos P, Seide S, Scholz EP, Katus HA, Schweizer PA (2020) Cryoballoon pulmonary vein isolation-mediated rise of sinus rate in patients with paroxysmal atrial fibrillation. Clin Res Cardiol doi: 10.1007/s00392-020-01659-0
11. Wiedmann F, Beyersdorf C, Zhou X, Büscher A, Kraft M, Nietfeld J, Walz TP, Unger LA, Loewe A, Schmack B, Ruhparwar A, Karck M, Thomas D, Borggrefe M, Seemann G, Katus HA, Schmidt C (2020) Pharmacologic TWIK-related acid-sensitive K+ channel (TASK-1) potassium channel onhibitor A293 facilitates acute cardioversion of paroxysmal atrial fibrillation in a porcine large animal model. J Am Heart Assoc. 9: e015751
12. Wiedmann F, Schlund D, Kraft M, Nietfeld J, Katus HA, Schmidt C, Thomas D (2020) Electrophysiological effects of non-vitamin K antagonist oral anticoagulants on atrial repolarizing potassium channels. Europace 22: 1409-1418
13. Zylla MM, Brachmann J, Lewalter T, Kuck KH, Andresen D, Willems S, Spitzer SG, Straube F, Schumacher B, Eckardt L, Hochadel M, Senges J, Katus HA, Thomas D (2020) Symptomatic arrhythmias after catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT): results from the German Ablation Registry. Clin Res Cardiol 109: 858-868
14. Zylla MM, Hochadel M, Andresen D, Brachmann J, Eckardt L, Hoffmann E, Kuck KH, Lewalter T, Schumacher B, Spitzer SG, Willems S, Senges J, Katus HA, Thomas D (2020) Ablation of atrial fibrillation in patients with hypertension-an analysis from the German Ablation Registry. J Clin Med 9: 2402
2019
15. Busch S, Eckardt L, Sommer P, Meyer C, Bonnemeier H, Thomas D, Neuberger HR, Tilz RR, Steven D, von Bary C, Kuniss M, Voss F, Estner HL (2019) Premature ventricular contractions and tachycardia in a structurally normal heart: Idiopathic PVC and VT. Herzschrittmacherther Elektrophysiol 30: 212-224
16. Darche FF, Rivinius R, Köllensperger E, Leimer U, Germann G, Seckinger A, Hose D, Schröter J, Bruehl C, Draguhn A, Gabriel R, Schmidt M, Koenen M, Thomas D, Katus HA, Schweizer PA (2019) Pacemaker cell characteristics of differentiated and HCN4-transduced human mesenchymal stem cells. Life Sci 232: 116620
17. Frommeyer G, Brachmann J, Ince H, Spitzer SG, Thomas D, Willems S, Schumacher B, Schirdewahn P, Lewalter T, Hochadel M, Senges J, Eckardt L (2019) Digitalis therapy is associated with higher comorbidities and poorer prognosis in patients undergoing ablation of atrial arrhythmias: data from the German Ablation Registry. Clin Res Cardiol 108: 1083-1092
18. Gessner G, Runge S, Koenen M, Heinemann SH, Koenen M, Haas J, Meder B, Thomas D, Katus HA, Schweizer PA (2019) ANK2 functionally interacts with KCNH2 aggravating long QT syndrome in a double mutation carrier. Biochem Biophys Res Commun 512: 845-851
19. Rapp F, Simoniello P, Wiedemann J, Bahrami K, Grünebaum V, Ktitareva S, Durante M, Lugenbiel P, Thomas D, Lehmann HI, Packer DL, Graeff C, Fournier C (2019) Biological cardiac tissue effects of high-energy heavy ions - investigation for myocardial ablation. Sci Rep 9: 5000
20. Rivinius R, Helmschrott M, Rahm AK, Darche FF, Thomas D, Bruckner T, Doesch AO, Ehlermann P, Katus HA, Zitron E. Risk factors and survival of patients with permanent pacemaker implantation after heart transplantation (2019) J Thorac Dis 11: 5440-5452
21. Schmidt C, Wiedmann F, Beyersdorf C, Zhao Z, El-Battrawy I, Lan H, Szabo G, Li X, Lang S, Korkmaz-Icöz S, Rapti K, Jungmann A, Ratte A, Müller OJ, Karck M, Seemann G, Akin I, Borggrefe M, Zhou XB, Katus HA, Thomas D (2019) Genetic ablation of TASK-1 (tandem of P domains in a weak inward rectifying K+ channel-related acid-sensitive K+ channel-1) (K2P3.1) K+ channels suppresses atrial fibrillation and prevents electrical remodeling. Circ Arrhythm Electrophysiol 12: e007465
22. Staudacher I, Seehausen S, Illg C, Lugenbiel P, Schweizer PA, Katus HA, Thomas D (2019) Cardiac K2P13.1 (THIK-1) two-pore-domain K+ channels: pharmacological regulation and remodeling in atrial fibrillation. Prog Biophys Mol Biol 144: 128-138
23. Staudacher I, Seehausen S, Gierten J, Illg C, Schweizer PA, Katus HA, Thomas D (2019) Cloning and characterization of zebrafish K2P13.1 (THIK-1) two-pore-domain K+ channels. J Mol Cell Cardiol 126: 96-104
24. Thomas D, Christ T, Fabritz L, Goette A, Hammwöhner M, Heijman J, Kockskämper J, Linz D, Odening KE, Schweizer PA, Wakili R, Voigt N (2019) German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management. Clin Res Cardiol 108: 577-599
25. Van den Bruck JH, Sultan A, Lüker J, Thomas D, Willems S, Weinmann K, Kuniss M, Hochadel M, Senges J, Andresen D, Brachmann J, Kuck KH, Tilz R, Steven D (2019) Remote vs. conventional navigation for catheter ablation of atrial fibrillation: insights from prospective registry data. Clin Res Cardiol 108: 298-308
26. Weigl I, Geschwill P, Reiss M, Bruehl C, Draguhn A, Koenen M, Sedaghat-Hamedani F, Meder B, Thomas D, Katus HA, Schweizer PA (2019) The C-terminal HCN4 variant P883R alters channel properties and acts as genetic modifier of atrial fibrillation and structural heart disease. Biochem Biophys Res Commun 519: 141-147
27. Wiedmann F, Schlund D, Faustino F, Kraft M, Ratte A, Thomas D, Katus HA, Schmidt C (2019) N-glycosylation of TREK-1/hK2P2.1 two-pore-domain potassium (K2P) channels. Int J Mol Sci 20: 5193
28. Xynogalos P, Lugenbiel P, Schweizer P, Katus H, Thomas D, Scholz EP (2019) Butterfly and reverse butterfly: usefulness of a resistance band to provoke exercise-induced arrhythmias during catheter ablation in a patient refractory to pharmacological stimulation. Clin Res Cardiol 108: 110-113
29. Yampolsky P, Koenen M, Mosqueira M, Geschwill P, Nauck S, Witzenberger M, Seyler C, Fink T, Kruska M, Bruehl C, Schwoerer AP, Ehmke H, Fink RHA, Draguhn A, Thomas D, Katus HA, Schweizer PA (2019) Augmentation of myocardial If dysregulates calcium homeostasis and causes adverse cardiac remodeling. Nat Commun 10: 3295
2018
30. Eckardt L, Frommeyer G, Sommer P, Steven D, Deneke T, Estner HL, Kriatselis C, Kuniss M, Busch S, Tilz RR, Bonnemeier H, von Bary C, Voss F, Meyer C, Thomas D, Neuberger HR (2018) Updated survey on interventional electrophysiology: 5-year follow-up of infrastructure, procedures, and training positions in Germany. JACC Clin Electrophysiol 4: 820-827
31. El-Battrawy I, Zhao Z, Lan H, Li X, Yücel G, Lang S, Sattler K, Schünemann JD, Zimmermann WH, Cyganek L, Utikal J, Wieland T, Bieback K, Bauer R, Ratte A, Pribe-Wolferts R, Rapti K, Nowak D, Wittig J, Thomas D, Most P, Katus HA, Ravens U, Schmidt C, Borggrefe M, Zhou XB, Müller OJ, Akin I (2018) Ion channel dysfunctions in dilated cardiomyopathy in limb-girdle muscular dystrophy. Circ Genom Precis Med 11: e001893
32. Lugenbiel P, Xynogalos P, Schweizer P, Katus HA, Thomas D, Scholz EP (2018) Successful localization and ablation of a Mahaim potential using a high-resolution mapping catheter after a failed conventional ablation attempt. Clin Res Cardiol 107: 607-610
33. Lugenbiel P, Govorov K, Rahm AK, Wieder T, Gramlich D, Syren P, Weiberg N, Seyler C, Katus HA, Thomas D (2018) Inhibition of histone deacetylases induces K+ channel remodeling and action potential prolongation in HL-1 atrial cardiomyocytes. Cell Physiol Biochem 49: 65-77
34. Rahm AK, Lugenbiel P, Schweizer PA, Katus HA, Thomas D (2018) Role of ion channels in heart failure and channelopathies. Biophys Rev 10: 1097-1106
35. Rahm AK, Katus HA, Thomas D (2018) Atrial fibrillation. In: Thomas D, Remme CA (eds.), Channelopathies in heart disease, Cardiac and vascular biology, doi: 10.1007/978-3-3-319-77819-9_12. Springer Nature.
36. Remme CA, Thomas D (2018) Channelopathies in heart disease - introduction and book overview. In: Thomas D, Remme CA (eds.), Channelopathies in heart disease, Cardiac and vascular biology, doi: 10.1007/978-3-3-319-77819-9_1. Springer Nature
37. Rivinius R, Helmschrott M, Ruhparwar A, Rahm AK, Darche FF, Thomas D, Bruckner T, Ehlermann P, Katus HA, Doesch AO (2018) Control of cardiac chronotropic function in patients after heart transplantation: effects of ivabradine and metoprolol succinate on resting heart rate in the denervated heart. Clin Res Cardiol 107: 138-147
38. Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Darche FF, Thomas D, Bruckner T, Katus HA, Ehlermann P, Doesch AO (2018) COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival. Clin Epidemiol 10: 1359-1369
39. Schmidt C, Wiedmann F, Gaubatz AR, Ratte A, Katus HA, Thomas D (2018) New targets for old drugs: cardiac glycosides inhibit atrial-specific K2P3.1 (TASK-1) channels. J Pharmacol Exp Ther 365: 614-623
40. Schmidt C, Wiedmann F, El-Battrawy I, Fritz M, Ratte A, Beller CJ, Lang S, Rudic B, Schimpf R, Akin I, Karck M, Borggrefe M, Katus HA, Zhou XB, Thomas D (2018) Reduced Na+ current in native cardiomyocytes of a Brugada syndrome patient associated with β-2-syntrophin mutation. Circ Genom Precis Med 11: e002263
41. Scholz EP, Fischer P, Lugenbiel P, Xynogalos P, Schweizer PA, Scherer D, Thomas D, Katus HA, Zitron E (2018) Novel approach to discriminate left bundle branch block from nonspecific intraventricular conduction delay using pacing-induced functional left bundle branch block. J Interv Card Electrophysiol 53: 347-355
42. Staudacher I, Illg C, Gierten J, Seehausen S, Schweizer PA, Katus HA, Thomas D (2018) Identification and functional characterization of zebrafish K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels. Eur J Pharmacol 831: 94-102
43. Staudacher S, Illg C, Chai S, Deschenes I, Seehausen S, Gramlich D, Müller ME, Wieder T, Rahm AK, Mayer C, Schweizer PA, Katus HA, Thomas D (2018) Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels. Naunyn Schmiedebergs Arch Pharmacol 391: 1119-1131
44. Voigt N, Mason F, Thomas D (2018) Report on the Ion Channel Symposium organized by the German Cardiac Society Working Group on Cellular Electrophysiology (AG 18). Herzschrittmacherther Elektrophysiol 29: 4-13
45. Wiedmann F, Schulte JS, Gomes B, Zafeiriou MP, Ratte A, Rathjens F, Fehrmann E, Scholz B, Voigt N, Müller FU, Thomas D, Katus HA, Schmidt C (2018) Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K2P) channels in murine disease models: focus on TASK-1. Basic Res Cardiol 113: 27
46. Zylla MM, Hillmann HAK, Proctor T, Kieser M, Scholz E, Zitron E, Katus HA, Thomas D (2018) Use of the wearable cardioverter-defibrillator (WCD) and WCD-based remote rhythm monitoring in a real-life patient cohort. Heart Vessels 33: 1390-1402
2017
47. Brachmann J, Lewalter T, Kuck KH, Andresen D, Willems S, Spitzer SG, Straube F, Schumacher B, Eckardt L, Danilovic D, Thomas D, Hochadel M, Senges J (2017) Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry. Eur Heart J 38: 1317-1326
48. Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pfister R, Thomas D, Fürnkranz A, Andrie RP, Napp A, Schmitt J, Karolyi L, Wakili R, Hilfiker-Kleiner D, Bauersachs J, Veltmann C (2017) Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol 106: 582-589
49. Koepple C, Scherer D, Seyler C, Scholz E, Thomas D, Katus HA, Zitron E (2017) Dual mechanism for inhibition of inwardly rectifying Kir2.x channels by quinidine involving direct pore block and PIP2-interference. J Pharmacol Exp Ther 36: 209-218
50. Lugenbiel P, Wenz F, Syren P, Geschwill P, Govorov K, Seyler C, Frank D, Schweizer PA, Franke J, Weis T, Bruehl C, Schmack B, Ruhparwar A, Karck M, Frey N, Katus HA, Thomas D (2017) TREK-1 (K2P2.1) K+ channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control. Basic Res Cardiol 112: 8
51. Lugenbiel P, Wenz F, Govorov K, Syren P, Katus HA, Thomas D (2017) Atrial myofibroblast activation and connective tissue formation in a porcine model of atrial fibrillation and reduced left ventricular function. Life Sci 181: 1-8
52. Prall M, Eichhorn A, Richter D, Lehmann HI, Constantinescu A, Kaderka R, Lugenbiel P, Thomas D, Bert C, Packer DL, Durante M, Graeff C (2017) Immobilization for carbon ion beam ablation of cardiac structures in a porcine model. Phys Med 43: 134-139
53. Richter D, Lehmann HI, Eichhorn A, Constantinescu AM, Kaderka R, Prall M, Lugenbiel P, Takami M, Thomas D, Bert C, Durante M, Packer DL, Graeff C (2017) ECG-based 4D-dose reconstruction of cardiac arrhythmia ablation with carbon ion beams: application in a porcine model. Phys Med Biol 62: 6869-6883
54. Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO (2017) The influence of surgical technique on early posttransplant atrial fibrillation - comparison of biatrial, bicaval, and total orthotopic heart transplantation. Ther Clin Risk Manag 13: 287-297
55. Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO (2017) Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation. Drug Des Devel Ther 11: 1827-1837
56. Rivinius R, Helmschrott M, Ruhparwar A, Rahm AK, Darche FF, Thomas D, Bruckner T, Ehlermann P, Katus HA, Doesch AO (2017) Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality. Ther Clin Risk Manag 13: 1399-1407
57. Scherer D, Schworm B, Seyler C, Xynogalos P, Scholz EP, Thomas D, Katus HA, Zitron E (2017) Inhibition of inwardly rectifying Kir2.x channels by the novel anti-cancer agent gambogic acid depends on both pore block and PIP2 interference. Naunyn Schmiedebergs Arch Pharmacol 390: 701-710
58. Schmidt C, Wiedmann F, Zhou XB, Heijman J, Voigt N, Ratte A, Lang S, Kallenberger S, Campana C, Weymann A, De Simone R, Szabo G, Ruhparwar A, Kallenbach K, Karck M, Ehrlich JR, Baczkó I, Borggrefe M, Ravens U, Dobrev D, Katus HA, Thomas D (2017) Inverse remodeling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation - Implications for patient-specific antiarrhythmic drug therapy. Eur Heart J 38: 1764-1774
59. Schmidt C, Wiedmann F, Kallenberger SM, Ratte A, Schulte JS, Scholz B, Müller FU, Voigt N, Zafeiriou MP, Ehrlich JR, Tochtermann U, Veres G, Ruhparwar A, Karck M, Katus HA, Thomas D (2017) Stretch-activated two-pore-domain (K2P) potassium channels in the heart: focus on atrial fibrillation and heart failure. Prog Biophys Mol Biol 130: 233-243
60. Schweizer PA, Koenen M, Katus HA, Thomas D (2017) A distinct cardiomyopathy: HCN4 syndrome comprising myocardial noncompaction, bradycardia, mitral valve defects, and aortic dilation. J Am Coll Cardiol 69: 1209-1210
61. Schweizer PA, Darche FF, Ullrich ND, Geschwill P, Greber B, Rivinius R, Seyler C, Müller-Decker K, Draguhn A, Utikal J, Koenen M, Katus HA, Thomas D (2017) Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells. Stem Cell Res Ther 8: 229
62. Seyler C, Scherer D, Köpple C, Kulzer M, Korkmaz S, Xynogalos P, Thomas D, Kaya Z, Scholz E, Backs J, Karle C, Katus HA, Zitron E (2017) Role of plasma membrane-associated AKAPs for the regulation of cardiac IK1 current by protein kinase A. Naunyn Schmiedebergs Arch Pharmacol 390: 493-503
63. Staudacher I, Nalpathamkalam AR, Uhlmann L, Illg C, Seehausen S, Akhavanpoor M, Buchauer A, Geis N, Lugenbiel P, Schweizer PA, Xynogalos P, Zylla MM, Scholz E, Zitron E, Katus HA, Thomas D (2017) Fully digital data processing during cardiovascular implantable electronic device follow-up in a high-volume tertiary center. Eur J Med Res 22: 41
64. Thomas D, Katus HA (2017) Herzrhythmusstörungen. Der Privatarzt 3: 14-15
2016
65. Bogossian H, Frommeyer G, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, Andresen D, Willems S, Spitzer SG, Deneke T, Thomas D, Hochadel M, Senges J, Eckardt L, Lemke B (2016) Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: Who benefits and who does not? Data from the German ablation registry. Int J Cardiol 214: 25-30
66. Hancox JC, James AF, Marrion NV, Zhang H, Thomas D (2016) Novel ion channel targets in atrial fibrillation. Expert Opin Ther Targets 20: 947-958
67. Kallenberger SM, Schmid C, Wiedmann F, Mereles D, Katus HA, Thomas D, Schmidt C (2016) A simple, non-invasive score to predict paroxysmal atrial fibrillation. PLoS One 11: e0163621
68. Lehmann HI, Graeff C, Simoniello P, Constantinescu A, Takami M, Lugenbiel P, Richter D, Eichhorn A, Prall M, Kaderka R, Fiedler F, Helmbrecht S, Fournier C, Erbeldinger N, Rahm AK, Rivinius R, Thomas D, Katus HA, Johnson SB, Parker KD, Debus J, Asirvatham SJ, Bert C, Durante M, Packer DL (2016) Feasibility study on cardiac arrhythmia ablation using high-energy heavy ion beams. Sci Rep 6: 38895
69. Loewe A, Wilhelms M, Schmid J, Krause MJ, Fischer F, Thomas D, Scholz EP, Dössel O, Seemann G (2016) Parameter estimation of ion current formulations requires hybrid optimization approach to be both accurate and reliable. Front Bioeng Biotechnol 3: 209
70. Lugenbiel P, Schweizer P, Katus HA, Thomas D (2016) Antiarrhythmic gene therapy - will biologics replace catheters, drugs and devices? Eur J Pharmacol 791: 264-273
71. Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO (2016) Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. Drug Des Devel Ther 10: 677-686
72. Scherer D, Seyler C, Xynogalos P, Scholz EP, Thomas D, Backs J, Andrassy M, Völkers M, Karle CA, Katus HA, Zitron E (2016) Inhibition of cardiac Kir current (IK1) by protein kinase C critically depends on PKCβ and Kir2.2. PLoS One 11: e0156181
73. Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabo G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczko I, Lugenbiel P, Schweizer PA, Donner B, Katus HA, Dobrev D, Thomas D (2016) Response to Letter regarding article, "Upregulation of K2P3.1 K+ current causes action potential shortening in patients with chronic atrial fibrillation". Circulation 133: e440-e441
74. Scholz E, Lugenbiel P, Schweizer PA, Xynogalos P, Seyler C, Zitron E, Becker R, Katus HA, Thomas D (2016) Efficacy, high procedural safety and rapid optimization of cryoballoon atrial fibrillation ablation in the hands of a new operator. J Atr Fibrillation 8: 1341
75. Thomas D, Eckardt L, Estner HL, Kuniss M, Meyer C, Neuberger HR, Sommer P, Steven D, Voss F, Bonnemeier H (2016) Typisches Vorhofflattern - Diagnostik und Therapie. Herzschrittmacherther Elektrophysiol 27: 46-56
76. Ukena C, Mahfoud F, Ewen S, Bollmann A, Hindricks G, Hoffmann BA, Linz D, Musat D, Pavlicek V, Scholz E, Thomas D, Willems S, Böhm M, Steinberg JS (2016) Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. Clin Res Cardiol 105: 873-879
77. Vermeer AM, Lodder EM, Thomas D, Duijkers FA, Marcelis C, van Gorselen EO, Fortner P, Buss SJ, Mereles D, Katus HA, Wilde AA, Bezzina CR, Boekholdt SM, Schweizer PA, Christiaans I (2016) Dilatation of the aorta ascendens forms part of the clinical spectrum of HCN4 mutations. J Am Coll Cardiol 67: 2313-2315
78. Wiedmann F, Schmidt C, Lugenbiel P, Staudacher I, Rahm AK, Seyler C, Schweizer PA, Katus HA, Thomas D (2016) Therapeutic targeting of two-pore-domain potassium (K2P) channels in the cardiovascular system. Clin Sci (Lond.) 130: 643-650
79. Zylla MM, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, Andresen D, Willems S, Hochadel M, Senges J, Katus HA, Thomas D (2016) Catheter ablation of atrial fibrillation in patients with concomitant sinus bradycardia - insights from the German Ablation Registry. J Electrocardiol 49: 117-123
80. Zylla MM, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, Andresen D, Willems S, Eckardt L, Tebbenjohanns J, Spitzer SG, Schumacher B, Hochadel M, Senges J, Katus HA, Thomas D (2016) Sex-related outcome of atrial fibrillation ablation - insights from the German Ablation Registry. Heart Rhythm 13: 1837-1844
81. Zylla MM, Thomas D (2016) Inherited arrhythmias - of channels, currents and swimming. Biophys J 110: 1017-1022
2015
82. Glasscock E, Voigt N, McCauley MD, Sun Q, Li N, Chiang DY, Zhou XB, Molina CE, Thomas D, Schmidt C, Skapura DG, Noebels JL, Dobrev D, Wehrens XHT (2015) Expression and function of Kv1.1 potassium channels in human atria from patients with atrial fibrillation. Basic Res Cardiol 110: 505
83. Li J, Franke J, Pribe-Wolferts R, Meder B, Ehlermann P, Mereles D, Andre F, Abdelrazek MA, Merten C, Schweizer PA, Becker R, Katus HA, Thomas D (2015) Effects of β-blocker therapy on electrocardiographic and echocardiographic characteristics of left ventricular noncompaction. Clin Res Cardiol 104: 241-249
84. Lugenbiel P, Wenz F, Govorov K, Schweizer PA, Katus HA, Thomas D (2015) Atrial fibrillation complicated by heart failure induces distinct remodeling of calcium cycling proteins. PLoS One 10: e0116395
85. Rivinius R, Helmschrott M, Koch V, Sedaghat-Hamedani F, Fortner P, Darche FF, Thomas D, Ruhparwar A, Schmack B, Karck M, Akhavanpoor M, Erbel C, Gleissner CA, Buss SJ, Mereles D, Ehlermann P, Katus HA, Doesch AO (2015) Constrictive pericarditis induced by remaining remnants of a left ventricular assist device in a heart transplanted patient. Case Rep Transplant 2015: 372698
86. Rivinius R, Darche FF, Campos B, Unterberg A, Schweizer L, Thomas D, Katus HA, Schweizer PA (2015) It's all in your head: sinus node dysfunction secondary to a sphenoid wing meningioma. Herzschrittmacherther Elektrophysiol 26: 300-302
87. Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabo G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczko I, Lugenbiel P, Schweizer PA, Donner B, Katus HA, Dobrev D, Thomas D (2015) Upregulation of K2P3.1 K+ current causes action potential shortening in patients with chronic atrial fibrillation. Circulation 132: 82-92
88. Scholz EP, Raake P, Thomas D, Vogel B, Katus HA, Blessing E (2015) Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation. Clin Res Cardiol 104: 79-84
89. Scholz EP, Raake P, Thomas D, Vogel B, Katus HA, Blessing E (2015) Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation: response to comments by Huang et al. Clin Res Cardiol 104: 194-195
90. Steven D, Bonnemeier H, Deneke T, Estner HL, Kriatselis C, Kuniss M, Luik A, Neuberger HR, Shin DI, Sommer P, Tilz RR, Thomas D, von Bary C, Voss F, Eckardt L (2015) How to approach the patient with supraventricular tachycardia in the EP lab: A systematic overview. Herzschrittmacherther Elektrophysiol 26: 167-172
91. von Bary C, Eckardt L, Steven D, Neuberger HR, Tilz RR, Bonnemeier H, Thomas D, Deneke T, Estner HL, Kuniss M, Luik A, Sommer P, Voss F, Meyer C, Shin DI, Kriatselis C (2015) AV nodal reentrant tachycardia: Diagnosis and therapy. Herzschrittmacherther Elektrophysiol 26: 351-358
92. Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP (2015) Anesthetic drug midazolam inhibits cardiac human ether-a-go-go-related gene channels: mode of action. Drug Des Devel Ther 9: 867-877
93. Zylla MM, Pohlmeier M, Hess A, Mereles D, Kieser M, Bruckner T, Scholz E, Zitron E, Schweizer PA, Katus HA, Thomas D (2015) Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran, rivaroxaban) and bridging therapy in patients with atrial fibrillation and flutter. Am J Cardiol 115: 635-640
2014
94. Fischer F, Vonderlin N, Seyler C, Zitron E, Korkmaz S, Szabó G, Thomas D, Katus HA, Scholz EP (2014) Isoenzyme-specific regulation of cardiac Kv1.5/Kvβ1.2 ion channel complex by protein kinase C: central role of PKCβII. Naunyn Schmiedebergs Arch Pharmacol 387: 469-476
95. Kisselbach J, Seyler C, Schweizer PA, Gerstberger R, Becker R, Katus HA, Thomas D (2014) Modulation of K2P2.1 and K2P10.1 K+ channel sensitivity to carvedilol by alternative mRNA translation initiation. Br J Pharmacol 171: 5182-5194
96. Li J, Maguy A, Elber Duverger J, Vigneault P, Comtois P, Shi Y, Tardif JC, Thomas D, Nattel S (2014) Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: potential significance in arrhythmogenesis and antiarrhythmic therapy. Heart Rhythm 11: 2092-2100
97. Rahm AK, Wiedmann F, Gierten J, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D (2014) Functional characterization of zebrafish K2P18.1 (TRESK) two-pore-domain K+ channels. Naunyn Schmiedebergs Arch Pharmacol 387: 291
98. Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO (2014) Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. Drug Des Dev Ther 9: 93-102
99. Schmidt C, Wiedmann F, Tristram F, Anand P, Wenzel W, Lugenbiel P, Schweizer PA, Katus HA, Thomas D (2014) Cardiac expression and atrial fibrillation-associated remodeling of K2P2.1 (TREK-1) K+ channels in a porcine model. Life Sci 97: 107-115
100. Schmidt C, Wiedmann F, Schweizer PA, Katus HA, Thomas D (2014) Inhibition of cardiac two-pore-domain K+ (K2P) channels - an emerging antiarrhythmic concept. Eur J Pharmacol 738: 250-255
101. Schmidt C, Wiedmann F, Langer C, Tristram F, Anand P, Wenzel W, Lugenbiel P, Schweizer PA, Katus HA, Thomas D (2014) Cloning, functional characterization and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure. Heart Rhythm 11: 1798-1805
102. Schweizer PA, Schröter J, Greiner S, Haas J, Yampolsky P, Mereles D, Buss SJ, Seyler C, Bruehl C, Draguhn A, Koenen M, Meder B, Katus HA, Thomas D (2014) The symptom complex of familial sinus node dysfunction and myocardial non-compaction is associated with mutations in the HCN4 channel. J Am Coll Cardiol 64: 757-767
103. Seyler C, Li J, Schweizer PA, Katus HA, Thomas D (2014) Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant - comparison with flecainide. Eur J Pharmacol 724: 51-57
104. Seyler C, Schweizer PA, Zitron E, Katus HA, Thomas D (2014) Vernakalant activates human cardiac K2P17.1 background K+ channels. Biochem Biophys Res Commun 451: 415-420
105. Staudacher I, Jehle J, Staudacher K, Pledl HW, Lemke D, Schweizer PA, Becker R, Katus HA, Thomas D (2014) hERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells. PLoS One 9: e88164
106. Thomas D (2014) Is antiarrhythmic gene therapy the future of atrial fibrillation management? Cardiac Rhythm News 25: 16
107. Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP (2014) Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action. Drug Des Devel Ther 8:2263-2271
108. Xynogalos P, Seyler C, Scherer D, Koepple C, Scholz EP, Thomas D, Katus HA, Zitron E (2014) Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224. Naunyn Schmiedebergs Arch Pharmacol 387: 1153-1161
2013
109. Duhme N*, Schweizer PA*, Thomas D, Becker R, Schröter J, Barends TR, Schlichting I, Draguhn A, Bruehl C, Katus HA, Koenen M (2013) Altered HCN4 channel C-linker interaction is associated with familial tachycardia-bradycardia syndrome and atrial fibrillation. Eur Heart J 34: 2768-2775
110. Jehle J, Ficker E, Wan X, Deschênes I, Kisselbach J, Wiedmann F, Staudacher I, Schmidt C, Schweizer P, Becker R, Katus H, Thomas D (2013) Mechanisms of zolpidem-induced long QT syndrome: Acute inhibition of recombinant hERG K+ channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol 168: 1215-1229
111. Li J, Seyler C, Wiedmann F, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D (2013) Anti-KCNQ1 K+ channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy. Cardiovasc Res 98: 496-503
112. Rillig A, Schmidt B, Steven D, Meyerfeldt U, DI Biase L, Wissner E, Becker R, Thomas D, Wohlmuth P, Gallinghouse GJ, Scholz E, Jung W, Willems S, Natale A, Ouyang F, Kuck KH, Tilz R (2013) Study design of the man and machine trial: a prospective international controlled noninferiority trial comparing manual with robotic catheter ablation for treatment of atrial fibrillation. J Cardiovasc Electrophysiol 24: 40-46
113. Sastry P, Rivinius R, Harvey R, Parker RA, Rahm AK, Thomas D, Nair S, Large SR (2013) The influence of endoscopic vein harvesting on outcomes after coronary bypass grafting: a meta-analysis of 267 525 patients. Eur J Cardiothorac Surg 44: 980-989
114. Schmidt C*, Wiedmann F*, Schweizer PA, Becker R, Katus HA, Thomas D (2013) Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channels. Eur J Pharmacol 721: 237-248
115. Thomas D, Bauer A, Katus HA, Becker R (2013) Antiarrhythmische Therapie der Zukunft: Gentherapie und Kanaltherapie bei Vorhofflimmern und ventrikulären Rhythmusstörungen. CardioNews 16: 18-20
116. Thomas D, Katus HA, Becker R (2013) Katheterablation des Vorhofflimmerns. Chancen und Herausforderungen im Jahr 2013. Kardiologe 7: 115-121
117. Trappe K*, Thomas D*, Bikou O, Kelemen K, Lugenbiel P, Voss F, Becker R, Katus HA, Bauer A (2013) Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3 - a preclinical pilot study. Eur Heart J 34: 147-157
2012
118. Aidery P, Kisselbach J, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Impaired ion channel function related to a common KCNQ1 mutation - implications for risk stratification in long QT syndrome 1. Gene 511: 26-33
119. Aidery P, Kisselbach J, Gaspar H, Baldea I, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Identification and functional characterization of the novel human ether-a-go-go-related gene (hERG) R744P mutant associated with hereditary long QT syndrome 2. Biochem Biophys Res Commun 418: 830-835
120. Gierten J, Hassel D, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Identification and functional characterization of zebrafish K2P10.1 (TREK2) two-pore-domain K+ channels. BBA - Biomembranes 1818: 33-41
121. Jehle J, Staudacher I, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Regulation of HL-1 cardiomyocyte apoptosis by EphA2 receptor tyrosine kinase phosphorylation and protection by lithocholic acid. Br J Pharmacol 167: 1563-1572
122. Kisselbach J, Schweizer PA, Gerstberger R, Becker R, Katus HA, Thomas D (2012) Enhancement of K2P2.1 (TREK1) background currents expressed in Xenopus oocytes by voltage-gated K+ channel β subunits. Life Sci 91: 377-383
123. Kulzer M*, Seyler C*, Welke F, Scherer D, Xynogalos P, Scholz EP, Thomas D, Becker R, Karle CA, Katus HA, Zitron E (2012) Inhibition of cardiac Kir2.1-2.3 channels by beta3 adrenoreceptor antagonist SR 59230A. Biochem Biophys Res Commun 424: 315-320
124. Li J, Warth A, Schnabel P, Schweizer PA, Buss SJ, Steen H, Becker R, Katus HA, Thomas D (2012) Electrophysiological findings in Fabry cardiomyopathy - Mapping the maze of risk stratification. Acta Cardiol 67: 481-485
125. Lugenbiel P, Bauer A, Kelemen K, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Biological heart rate reduction through genetic suppression of Gαs protein in the sinoatrial node. J Am Heart Assoc 1: jah3-e000372
126. Lugenbiel P*, Thomas D*, Kelemen K, Trappe K, Bikou O, Schweizer PA, Voss F, Becker R, Katus HA, Bauer A (2012) Genetic suppression of Gαs protein provides rate control in atrial fibrillation. Basic Res Cardiol 107: 1-12
127. Rahm AK*, Gierten J*, Kisselbach J, Staudacher I, Staudacher K, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Protein kinase C-dependent activation of human K2P18.1 K+ channels. Br J Pharmacol 166: 764-773
128. Schmidt C*, Wiedmann F*, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Novel electrophysiological properties of dronedarone: Inhibition of human cardiac two-pore-domain potassium (K2P) channels. Naunyn Schmiedebergs Arch Pharmacol 385: 1003-1016
129. Schmidt C, Wiedmann F, Schweizer PA, Katus HA, Thomas D (2012) Kardiale Zwei-Porendomänen-Kaliumkanäle (K2P): Physiologie, Pharmakologie und therapeutisches Potenzial. Dtsch Med Wochenschr 137: 1654-1658
130. Schueler M*, Vafaie M*, Becker R, Biener M, Thomas D, Mueller M, Giannitsis E, Katus HA (2012) Prevalence, kinetic changes and possible reasons of elevated cardiac troponin T in patients with AV nodal re-entrant tachycardia. Acute Card Care 14: 131-137
131. Schueler M*, Voss F*, Bauer A, Thomas D, Kelemen K, Katus HA, Becker R (2012) Atrioventricular delay programming in cardiac resynchronization therapy devices: fixed or adaptive?: A randomized monocenter trial. J Electrocardiol 45: 783-786
132. Schweizer PA, Korosoglou G, Thomas D, Aulmann S, Remppis A, Witzens-Harig M, Katus HA (2012) Chest pain, shortness of breath, and palpitations unmask an unexpected diagnosis. Circulation 125: 843-846
133. Seyler C, Duthil-Straub E, Zitron E, Gierten J, Scholz EP, Fink RHA, Karle CA, Becker R, Katus HA, Thomas D (2012) TASK1 (K2P3.1) K+ current inhibition by endothelin-1 is mediated by Rho kinase-dependent channel phosphorylation. Br J Pharmacol 165: 1467-1475
134. Soucek R*, Thomas D*, Kelemen K, Bikou O, Seyler C, Voss F, Becker R, Koenen M, Katus HA, Bauer A (2012) Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm 9: 265-272
135. Thomas D (2012) Dronedaron. Arzneimittel-, Therapie-Kritik & Medizin und Umwelt 4: 305-308
136. Thomas D, Katus HA, Becker R (2012) Aktueller Stellenwert von Dronedaron in der Therapie des Vorhofflimmerns. Kardiologie up2date 8: 96-102
137. Thomas D, Scholz EP, Schweizer PA, Katus HA, Becker R (2012) Initial experience with robotic navigation for catheter ablation of paroxysmal and persistent atrial fibrillation. J Electrocardiol 45: 95-101
2011
138. Aidery P*, Kisselbach J*, Schweizer PA, Becker R, Katus HA, Thomas D (2011) Biophysical properties of mutant KCNQ1 S277L channels linked to hereditary long QT syndrome with phenotypic variability. BBA - Mol Basis Dis 1812: 488-494
139. Bikou O*, Thomas D*, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA, Bauer A (2011) Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 92: 218-225
140. Dennis AT, Nassal D, Deschenes I, Thomas D, Ficker E (2011) Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG. J Biol Chem 286: 34413-34425
141. Jehle J, Schweizer PA, Katus HA, Thomas D (2011) Novel roles for hERG K+ channels in cell proliferation and apoptosis. Cell Death Dis 2: e193
142. Schmidt C*, Kisselbach J*, Schweizer PA, Katus HA, Thomas D (2011) The pathology and treatment of cardiac arrhythmias: Focus on atrial fibrillation. Vasc Health Risk Manag 7: 193-202
143. Scholz EP, Welke F, Joss N, Seyler C, Zhang W, Scherer D, Völkers M, Bloehs R, Thomas D, Katus HA, Karle CA, Zitron E (2011) Central role of PKCα in isoenzyme-selective regulation of cardiac transient outward current I(to) and Kv4.3 channels. J Mol Cell Cardiol 51: 722-729
144. Schweizer PA, Becker R, Katus HA, Thomas D (2011) Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther 5: 27-39
145. Staudacher I, Wang L, Wan X, Obers S, Wenzel W, Tristram F, Koschny R, Staudacher K, Kisselbach J, Koelsch P, Schweizer PA, Katus HA, Ficker E, Thomas D (2011) hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn-Schmiedebergs Arch Pharmacol 383: 119-139
146. Staudacher K*, Baldea I*, Kisselbach J*, Staudacher I, Rahm AK, Schweizer PA, Becker R, Katus HA, Thomas D (2011) Alternative splicing determines mRNA translation initiation and function of human K2P10.1 K+ channels. J Physiol 589: 3709-3720
147. Staudacher K*, Staudacher I*, Ficker E, Seyler C, Gierten J, Kisselbach J, Rahm AK, Trappe K, Schweizer PA, Becker R, Katus HA, Thomas D (2011) Carvedilol targets human K2P3.1 (TASK1) K+ leak channels. Br J Pharmacol 163: 1099-1110
148. Thomas D, Katus HA, Voss F (2011) Asymptomatic pulmonary vein stenosis after cryoballoon catheter ablation of paroxysmal atrial fibrillation. J Electrocardiol 44: 473-476
149. Vogel B*, Thomas D*, Mereles D, Rottbauer W, Katus HA (2011) Systemic embolization and myocardial infarction due to clinically unrecognized left atrial myxoma. Case Report Med 2011: 159024
2010
150. Chen J, Chen K, Sroubek J, Wu ZY, Thomas D, Bian JS, McDonald TV (2010) Post-transcriptional control of HERG potassium channel protein by α-adrenergic receptor stimulation. Mol Pharmacol 78: 186-197
151. Gierten J, Ficker E, Bloehs R, Schweizer PA, Zitron E, Scholz EP, Karle C, Katus HA, Thomas D (2010) The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone. Naunyn-Schmiedebergs Arch Pharmacol 381: 261-270
152. Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H, Bloehs R, Kisselbach J, Karle CA, Schweizer PA, Katus HA, Thomas D (2010) Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn-Schmiedebergs Arch Pharmacol 381: 385-400
153. Schweizer PA, Becker R, Katus HA, Thomas D (2010) Successful acute and long-term management of electrical storm in Brugada syndrome using orciprenaline and quinine/quinidine. Clin Res Cardiol 99: 467-470
154. Schweizer PA*, Duhme N*, Thomas D, Becker R, Zehelein J, Draguhn A, Bruehl C, Katus HA, Koenen M (2010) cAMP sensitivity of HCN pacemaker channels determines basal heart rate but is not critical for autonomic rate control. Circ Arrhythm Electrophysiol 3: 542-552
155. Staudacher I, Schweizer PA, Katus HA, Thomas D (2010) hERG: Protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel 13: 23-30
156. Thomas D*, Khalil M*, Alter M, Schweizer PA, Karle CA, Wimmer AB, Licka M, Katus HA, Koenen M, Ulmer HE, Zehelein J (2010) Biophysical characterization of KCNQ1 P320 mutations linked to long QT syndrome 1. J Mol Cell Cardiol 48: 230-237
2009
157. Scherer D*, Hassel D*, Bloehs R, Zitron E, von Löwenstern K, Seyler C, Thomas D, Konrad F, Bürgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP (2009) Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol 156: 226-236
158. Scholz EP, Niemer N, Hassel D, Zitron E, Bürgers HF, Bloehs R, Seyler C, Scherer D, Thomas D, Kathöfer S, Katus HA, Rottbauer W, Karle CA (2009) Biophysical properties of zebrafish ether-a-go-go-related gene potassium channels. Biochem Biophys Res Commun 381: 159-164
159. Schweizer PA, Yampolsky P, Malik R, Thomas D, Zehelein J, Katus HA, Koenen M (2009) Transcription profiling of HCN-channel isotypes throughout mouse development. Basic Res Cardiol 104: 621-629
160. Thomas D, Goldstein SAN (2009) Two-P-domain (K2P) potassium channels: leak conductance regulators of excitability. In: Squire LR (Hrsg.): Encyclopedia of Neuroscience, 9: 1207-1220. Oxford: Academic Press
2008
161. Gierten J, Ficker E, Bloehs R, Schlömer K, Kathöfer S, Scholz E, Zitron E, Kiesecker C, Bauer A, Becker R, Katus HA, Karle CA, Thomas D (2008) Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein. Br J Pharmacol 154: 1680-1690
162. Scherer D, von Löwenstern K, Zitron E, Scholz EP, Bloehs R, Kathöfer S, Thomas D, Bauer A, Katus HA, Karle CA, Kiesecker C (2008) Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. Naunyn-Schmiedebergs Arch Pharmacol 378: 73-83
163. Thomas D, Bloehs R, Koschny R, Ficker E, Sykora J, Kiehn J, Schlömer K, Gierten J, Kathöfer S, Zitron E, Scholz EP, Kiesecker C, Katus HA, Karle CA (2008) Doxazosin induces apoptosis of cells expressing hERG K+ channels. Eur J Pharmacol 579: 98-103
164. Thomas D, Plant LD, Wilkens CM, McCrossan ZA, Goldstein SAN (2008) Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium. Neuron 58: 859-870
165. Zitron E, Günth M, Scherer D, Kiesecker C, Kulzer M, Bloehs R, Scholz EP, Thomas D, Weidenhammer C, Bauer A, Katus HA, Karle CA (2008) Kir2.x inward rectifier potassium channels are differentially regulated by adrenergic alpha(1A) receptors. J Mol Cell Cardiol 44: 84-94
2007
166. Kelemen K*, Kiesecker C*, Zitron E, Bauer A, Scholz E, Bloehs R, Thomas D, Greten J, Remppis A, Schoels W, Katus HA, Karle CA (2007) Green tea flavonoid epidallocatechin-3-gallate (EGCG) inhibits cardiac hERG potassium channels. Biochem Biophys Res Commun 364: 429-435
167. Scherer D*, Kiesecker C*, Kulzer M, Gunth M, Scholz EP, Kathofer S, Thomas D, Maurer M, Kreuzer J, Bauer A, Katus HA, Karle CA, Zitron E (2007) Activation of inwardly rectifying Kir2.x potassium channels by beta(3)-adrenoceptors is mediated via different signalling pathways with a predominant role of PKC for Kir2.1 and of PKA for Kir2.2. Naunyn-Schmiedebergs Arch Pharmacol 375: 311-322
168. Scholz EP, Konrad FM, Weiss DL, Zitron E, Kiesecker C, Bloehs R, Kulzer M, Thomas D, Kathöfer S, Bauer A, Maurer MH, Seemann G, Katus HA, Karle CA (2007) Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. Naunyn-Schmiedebergs Arch Pharmacol 376: 275-284
169. Scholz EP*, Zitron E*, Kiesecker C, Thomas D, Kathofer S, Kreuzer J, Bauer A, Katus HA, Remppis A, Karle CA, Greten J (2007) Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656. Nutr Metab Cardiovasc Dis 17: 666-675
170. Zhang W*, Zitron E*, Hömme M, Kihm L, Morath C, Scherer D, Hegge S, Thomas D, Schmitt CP, Zeier M, Katus H, Karle C, Schwenger V (2007) Aquaporin-1 channel function is positively regulated by protein kinase C. J Biol Chem 282: 20933-20940
2006
171. Kiesecker C*, Alter M*, Kathöfer S, Zitron E, Scholz EP, Thomas D, Kreuzer J, Katus HA, Bauer A, Karle CA (2006) Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels. Naunyn-Schmiedebergs Arch Pharmacol 373: 212-220
172. Kiesecker C, Zitron E, Scherer D, Lueck S, Bloehs R, Scholz EP, Pirot M, Kathofer S, Thomas D, Kreye VA, Kiehn J, Borst MM, Katus HA, Schoels W, Karle CA (2006) Regulation of cardiac inwardly rectifying potassium current IK1 and Kir2.x channels by endothelin-1. J Mol Med 84: 46-56
173. Scholz EP, Alter M, Zitron E, Kiesecker C, Kathofer S, Thomas D, Kreye VA, Kreuzer J, Becker R, Katus HA, Greten J, Karle CA (2006) In vitro modulation of HERG channels by organochlorine solvent trichlormethane as potential explanation for proarrhythmic effects of chloroform. Toxicol Lett 165: 156-166
174. Thomas D, Karle CA, Kiehn J (2006) The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Design 12: 2271-2283
175. Zehelein J*, Kathoefer S*, Khalil M, Alter M, Thomas D, Brockmeier K, Ulmer HE, Katus HA, Koenen M (2006) Skipping of exon 1 in the KCNQ1 gene causes Jervell and Lange-Nielsen syndrome. J Biol Chem 281: 35397-35403
2005
176. Kathofer S*, Thomas D*, Karle CA (2005) The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 23: 217-230
177. Scholz EP*, Zitron E*, Kiesecker C, Luck S, Thomas D, Kathofer S, Kreye VAW, Katus HA, Kiehn J, Schoels W, Karle CA (2005) Inhibition of HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. Naunyn-Schmiedebergs Arch Pharmacol 371: 516-525
178. Thomas D*, Wimmer AB*, Karle CA*, Licka M, Alter M, Khalil M, Ulmer HE, Kathöfer S, Kiehn J, Katus HA, Schoels W, Koenen M, Zehelein J (2005) Dominant-negative IKs suppression by KCNQ1-ΔF339 potassium channels linked to Romano-Ward syndrome. Cardiovasc Res 67: 487-497
179. Zitron E, Scholz EP, Kiesecker C, Pirot M, Kathofer S, Thomas D, Kiehn J, Katus HA, Becker R, Karle CA (2005) Molecular basis of primary electrical heart diseases. Herzschrittmacherther Elektrophysiol 16: 229-238
180. Zitron E*, Scholz E*, Owen RW, Luck S, Kiesecker C, Thomas D, Kathofer S, Niroomand F, Kiehn J, Kreye VA, Katus HA, Schoels W, Karle CA (2005) QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation 111: 835-838
2004
181. Kiesecker C, Zitron E, Luck S, Bloehs R, Scholz EP, Kathofer S, Thomas D, Kreye VA, Katus HA, Schoels W, Karle CA, Kiehn J (2004) Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action. Naunyn-Schmiedebergs Arch Pharmacol 370: 423-435
182. Thomas D, Becker R, Katus HA, Schoels W, Karle CA (2004) Radiation therapy-induced electrical reset of an implantable cardioverter defibrillator device located outside the irradiation field. J Electrocardiol 37: 73-74
183. Thomas D*, Hammerling BC*, Wimmer AB*, Wu K, Ficker E, Kuryshev YA, Scherer D, Kiehn J, Katus HA, Schoels W, Karle CA (2004) Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X). Cardiovasc Res 64: 467-476
184. Thomas D*, Hammerling BC*, Wu K, Wimmer AB, Ficker EK, Kirsch GE, Kochan MC, Wible BA, Scholz EP, Zitron E, Kathöfer S, Kreye VAW, Katus HA, Schoels W, Karle CA, Kiehn J (2004) Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol 142: 485-494
185. Thomas D, Karle CA, Kiehn J (2004) Modulation of HERG potassium channel function by drug action. Ann Med 36 (suppl. 1):41-46
186. Thomas D, Kiehn J, Katus HA, Karle CA (2004) Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, IKr, and the underlying hERG ion channel. Basic Res Cardiol 99: 279-287
187. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA (2004) Inhibition of human ether-a-go-go-related gene potassium channels by α1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn-Schmiedebergs Arch Pharmacol 369: 462-472
188. Thomas D, Wu K, Wimmer AB, Zitron E, Hammerling BC, Kathöfer S, Lueck S, Bloehs R, Kreye VAW, Kiehn J, Katus HA, Schoels W, Karle CA (2004) Activation of cardiac human ether-a-go-go-related gene (hERG/IKr) potassium currents is regulated by α1A-adrenoceptors. J Mol Med 82: 826-837
189. Zehelein J*, Thomas D*, Khalil M, Wimmer AB, Koenen M, Licka M, Wu K, Kiehn J, Brockmeier K, Kreye VAW, Karle CA, Katus HA, Ulmer HE, Schoels W (2004) Identification and characterization of a novel KCNQ1 mutation in a family with Romano-Ward syndrome. BBA - Mol Basis Dis 1690: 185-192
190. Zitron E, Kiesecker C, Luck S, Kathofer S, Thomas D, Kreye VA, Kiehn J, Katus HA, Schoels W, Karle CA (2004) Human cardiac inwardly rectifying current I(Kir2.2) is upregulated by activation of protein kinase A. Cardiovasc Res 63: 520-527
191. Zitron E, Kiesecker C, Scholz EP, Lück S, Bloehs R, Kathöfer S, Thomas D, Kiehn J, Kreye VA, Katus HA, Schoels W, Karle CA (2004) Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn-Schmiedebergs Arch Pharmacol 370: 146-156
2003
192. Kathöfer S, Röckl K, Zhang W, Thomas D, Katus H, Kiehn J, Karle C (2003) Human β3-adrenoceptors couple to KvLQT1/minK potassium channels via protein kinase C phosphorylation of the KvLQT1 protein. Naunyn-Schmiedebergs Arch Pharmacol 368: 119-126
193. Scholz EP*, Zitron E*, Kiesecker C, Lueck S, Kathöfer S, Thomas D, Weretka S, Peth S, Kreye VAW, Schoels W, Katus HA, Kiehn J, Karle CA (2003) Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired long QT syndrome by antiparkinsonian drug budipine. Naunyn-Schmiedebergs Arch Pharmacol 368: 404-414
194. Thomas D, Gut B, Karsai S, Wimmer AB, Wu K, Wendt-Nordahl G, Zhang W, Kathöfer S, Schoels W, Katus HA, Kiehn J, Karle CA (2003) Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn-Schmiedebergs Arch Pharmacol 368: 41-48
195. Thomas D*, Kathöfer S*, Zhang W, Wu K, Wimmer AB, Zitron E, Kreye VAW, Katus HA, Schoels W, Karle CA, Kiehn J (2003) Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. Br J Pharmacol 140: 996-1002
196. Thomas D, Kiehn J, Katus HA, Karle CA (2003) Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): Molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res 60: 239-245
197. Thomas D, Wu K, Kathöfer S, Katus HA, Schoels W, Kiehn J, Karle CA (2003) The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 139: 567-574
198. Thomas D, Zhang W, Wu K, Wimmer AB, Gut B, Wendt-Nordahl G, Kathöfer S, Kreye VAW, Katus HA, Schoels W, Kiehn J, Karle CA (2003) Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein. Cardiovasc Res 59: 14-26
2002
199. Karle CA*, Thomas D*, Kiehn J (2002) The antiarrhythmic drug BRL-32872. Cardiovasc Drug Rev 20: 111-120
200. Karle CA, Zitron E, Zhang W, Wendt-Nordahl G, Kathöfer S, Thomas D, Gut B, Scholz E, Vahl CF, Katus HA, Kiehn J (2002) The human cardiac inwardly-rectifying K+ channel Kir2.1b is inhibited by direct protein kinase C - dependent regulation in human isolated cardiomyocytes and in an expression system. Circulation 106: 1493-1499
201. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J (2002) The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300: 543-548
202. Wei Z*, Thomas D*, Karle CA, Kathöfer S, Schenkel J, Kreye VAW, Ficker E, Wible BA, Kiehn J (2002) Protein kinase A-mediated phosphorylation of HERG potassium channels in a human cell line. Chin Med J 115: 668-676
203. Zitron E*, Karle CA*, Wendt-Nordahl G, Kathöfer S, Zhang W, Thomas D, Weretka S, Kiehn J (2002) Bertosamil blocks HERG potassium channels in their open and inactivated states. Br J Pharmacol 137: 221-228
2001
204. Karle C, Kreye VAW, Thomas D, Röckl K, Kathöfer S, Zhang W, Kiehn J (2001) Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 49: 361-370
205. Lacerda AE, Kramer J, Shen KZ, Thomas D, Brown AM (2001) Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J 3 (Suppl. K): K23-K30
206. Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J (2001) High affinity blockade of HERG human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 297: 735-761
2000
207. Ficker E, Thomas D, Viswanathan PC, Dennis AT, Priori SG, Napolitano C, Memmi M, Wible BA, Kaufman ES, Iyengar S, Schwartz PJ, Rudy Y, Brown AM (2000) Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. Am J Physiol 279: H1748-H1756
208. Kathöfer S*, Zhang W*, Karle C, Thomas D, Schoels W, Kiehn J (2000) Functional coupling of human β3-adrenoceptors to the KvLQT1/minK potassium channel. J Biol Chem 275: 26743-26747
1999
209. Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W (1999) Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedebergs Arch Pharmacol 359: 212-219
210. Thomas D*, Zhang W*, Karle CA, Kathöfer S, Schöls W, Kübler W, Kiehn J (1999) Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J Biol Chem 274: 27457-27462
1998
211. Kiehn J, Karle CA, Thomas D, Yao X, Brachmann J, Kübler W (1998) HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways. J Biol Chem 273: 25285-25291

[*gleichberechtigte Erst- bzw. Letztautoren]